GlassScriptPhysician profile
Albert B Empedrad
NPI 1699899914
$3,679.38
in general payments reported to CMS, 2019-2025
27 companies · $362 in 2025
The $362 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $582 · 2020: $803 · 2021: $599 · 2022: $601 · 2023: $291 · 2024: $441 · 2025: $362.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,094.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,094.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $709.74 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $644.66 | 2019-2022 | |
| Novo Nordisk INC | $435.10 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $434.30 | 2019-2025 | Jardiance, Trulicity, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $293.34 | 2019-2025 | Jardiance, Synjardy |
| Abbott Laboratories | $267.02 | 2019-2025 | Freestyle Libre 3 |
| Amneal Pharmaceuticals LLC | $187.40 | 2020-2024 | Unithroid |
| Merck Sharp & Dohme LLC | $108.81 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $78.94 | 2022-2025 | |
| Xeris Pharmaceuticals, INC. | $74.92 | 2022-2025 | Gvoke Hypopen, Recorlev |
| Corcept Therapeutics | $73.83 | 2020-2022 | |
| Insulet Corporation | $50.79 | 2019-2025 | Omnipod |
| Medtronic, INC. | $43.21 | 2024 | Intellis Adaptivestim |
| Dexcom, INC. | $33.88 | 2022-2024 | Dexcom G6 Transmitter |
| Alexion Pharmaceuticals, INC. | $31.63 | 2020-2025 | Strensiq |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $29.65 | 2022-2025 | Tepezza |
| Ascensia Diabetes Care US INC. | $26.64 | 2024 | |
| Halozyme INC | $23.39 | 2023 | |
| Abbvie INC. | $18.57 | 2025 | |
| Valeritas, INC. | $15.21 | 2019 | |
| Medtronic Minimed, INC. | $14.65 | 2020 | |
| Shire North American Group INC | $14.45 | 2019 | |
| Ibsa Pharma INC. | $14.27 | 2020 | |
| Zealand Pharma US, INC. | $13.95 | 2022 | |
| Antares Pharma, INC. | $13.84 | 2023 | Nocdurna, Xyosted, Tlando |
| Ascendis Pharma Endocrinology INC | $13.77 | 2025 | Yorvipath |
| Ultragenyx Pharmaceutical INC. | $13.42 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Empedrad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.